News
COCP
1.390
-0.71%
-0.010
Weekly Report: what happened at COCP last week (0420-0424)?
Weekly Report · 3d ago
Cocrystal Pharma files $150M mixed securities shelf
TipRanks · 6d ago
Cocrystal Pharma Files $150M Shelf Offering To Sell Stock, Warrants, And Other Securities
Benzinga · 6d ago
COCRYSTAL PHARMA INC - FILES TO OFFER UP TO $150 MLN IN SECURITIES - SEC FILING
Reuters · 6d ago
Weekly Report: what happened at COCP last week (0413-0417)?
Weekly Report · 04/20 09:28
Cocrystal Pharma publishes investor presentation on antiviral pipeline for norovirus, influenza, coronaviruses
PUBT · 04/15 18:42
Cocrystal Pharma (COCP) Price Target Increased by 33.33% to 8.16
NASDAQ · 04/15 03:26
Weekly Report: what happened at COCP last week (0406-0410)?
Weekly Report · 04/13 09:29
3 Penny Stocks to Watch Now, 4/7/26
TipRanks · 04/07 14:09
Why Cocrystal Pharma Shares Are Cooling Off Monday?
Benzinga · 04/06 13:28
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 04/06 12:05
Weekly Report: what happened at COCP last week (0330-0403)?
Weekly Report · 04/06 09:29
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 04/02 17:05
BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
Reuters · 04/02 15:48
BUZZ-Cocrystal Pharma soars as FDA fast-tracks oral norovirus drug
Reuters · 04/02 15:27
Nasdaq Down 1%; US Initial Jobless Claims Fall
Benzinga · 04/02 14:44
Cocrystal Pharma Shares Soar After FDA Grants Fast Track Status To CDI-988
Benzinga · 04/02 14:03
Cocrystal Pharma Wins FDA Fast Track for Norovirus Drug
TipRanks · 04/02 13:39
BUZZ-U.S. STOCKS ON THE MOVE-Energy firms, Estee Lauder, HMH Holding
Reuters · 04/02 13:12
BUZZ-Cocrystal Pharma rises as FDA fast-tracks oral norovirus drug
Reuters · 04/02 12:25
More
Webull provides a variety of real-time COCP stock news. You can receive the latest news about Cocrystal Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About COCP
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.